Rhumbline Advisers acquired a new stake in Xeris Pharmaceuticals Inc (NASDAQ:XERS) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 23,061 shares of the company’s stock, valued at approximately $232,000.
A number of other large investors have also recently bought and sold shares of XERS. Bank of New York Mellon Corp acquired a new position in Xeris Pharmaceuticals in the 3rd quarter valued at approximately $262,000. Vanguard Group Inc. raised its holdings in Xeris Pharmaceuticals by 920.3% in the 3rd quarter. Vanguard Group Inc. now owns 255,064 shares of the company’s stock valued at $4,484,000 after acquiring an additional 230,064 shares in the last quarter. New York State Common Retirement Fund acquired a new position in Xeris Pharmaceuticals in the 4th quarter valued at approximately $66,000. BlackRock Inc. raised its holdings in Xeris Pharmaceuticals by 63.5% in the 4th quarter. BlackRock Inc. now owns 645,035 shares of the company’s stock valued at $10,966,000 after acquiring an additional 250,619 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Xeris Pharmaceuticals by 1.5% in the 4th quarter. Northern Trust Corp now owns 74,423 shares of the company’s stock valued at $1,265,000 after acquiring an additional 1,089 shares in the last quarter. Hedge funds and other institutional investors own 59.43% of the company’s stock.
Xeris Pharmaceuticals stock opened at $9.50 on Friday. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $248.93 million and a price-to-earnings ratio of -1.90. Xeris Pharmaceuticals Inc has a 12 month low of $6.85 and a 12 month high of $27.98.
Xeris Pharmaceuticals (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.31). The firm had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.30 million. Xeris Pharmaceuticals had a negative net margin of 2,997.96% and a negative return on equity of 75.93%. As a group, analysts expect that Xeris Pharmaceuticals Inc will post -4.09 earnings per share for the current fiscal year.
In other Xeris Pharmaceuticals news, insider Steven Prestrelski sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $9.56, for a total value of $95,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.43% of the company’s stock.
WARNING: “Rhumbline Advisers Invests $232,000 in Xeris Pharmaceuticals Inc (NASDAQ:XERS) Stock” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2019/06/14/rhumbline-advisers-invests-232000-in-xeris-pharmaceuticals-inc-nasdaqxers-stock.html.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
See Also: What is the formula for the cash asset ratio?
Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Pharmaceuticals Inc (NASDAQ:XERS).
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.